



**CONTACT:** Trish Cetrone  
925-787-4283  
[tcetrone@chasepr.com](mailto:tcetrone@chasepr.com)  
Chase Communications

Mike Ford  
707-256-2403  
[mford@santeninc.com](mailto:mford@santeninc.com)  
Santen Inc.

### **SANTEN ANNOUNCES DIRECTOR OF BUSINESS DEVELOPMENT**

**NAPA, Calif. (March 9, 2009)** – Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) announced Craig Skenes as the company's new Director of Business Development.

"The US market is a key component of Santen's strategy to increase our global presence in ophthalmology," says Santen President and Chief Executive Officer Adrienne Graves, PhD. "Craig's extensive experience in ophthalmic business development allows us to increase our efforts to add innovative products to our global product pipeline."

Skenes, who most recently was the Director of Business Development for ISTA Pharmaceuticals, brings a strong business development and financial analysis perspective to Santen based on his work with Gilead Sciences, Watson Pharmaceuticals and NeXstar Pharmaceuticals.

In his new role at Santen, Skenes will identify, structure and negotiate new business opportunities for in-licensing, out licensing and acquisitions for both the US and global markets.

Santen Inc. continues to aggressively expand its clinical and business development efforts to support the company's international expansion in the dry eye, retinal and glaucoma therapeutic markets.

"I am excited to have someone with Craig's ophthalmic business development experience join the team," says Schalon Newton, EDM, Santen's Vice President of Strategic Marketing & Business Development. "The capabilities and relationships Craig brings to Santen will help us further accelerate our business development activities in the U.S. market."

Currently, Santen Inc. has four innovative compounds in U.S. clinical development for the glaucoma and corneal disorder therapeutic categories.

Santen has four FDA-approved drugs currently marketed in the U.S. Since late 2003, Vistakon Pharmaceuticals has had sole U.S. distribution rights for these products: IQIIX<sup>®</sup> (levofloxacin ophthalmic solution) 1.5%, QUIXIN<sup>®</sup> (levofloxacin ophthalmic solution) 0.5%, BETIMOL<sup>®</sup> (timolol ophthalmic solution) 0.25%, 0.5% and ALAMAST<sup>®</sup> (pemirolast potassium ophthalmic solution) 0.1%. Santen continues to have responsibility for manufacturing, clinical and regulatory activities associated with all four of these products.

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a billion-dollar global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned Napa, California-based Santen Inc. Santen's global product pipeline includes many more prescription pharmaceuticals in varying clinical trial phases. A detailed listing, as well as additional corporate information, is available online at [www.santeninc.com](http://www.santeninc.com).

##-##

Editor's Note: Color and B&W headshots of Skenes are available. Contact Trish Cetrone at [tcetrone@chasepr.com](mailto:tcetrone@chasepr.com).